Winter 2013

Transcription

Winter 2013

Winter 2013
In This Issue:
American Society of
Hematology (ASH),
American Society for
Therapeutic Radiation
Onocology (ASTRO),
San Antonio Breast
Cancer Symposium
(SABCS), Chicago
Multidisciplinary
Symposium in Thoracic
Oncology, Society for
Neuro Oncology (SNO),
ASCO, EORTC and NCI
- Markers in Cancer),
International Society for
Quality of Life Research
(ISOQOL) and Others
Cooperative Group
Abstracts:
Breast Cancer
CNS Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Leukemia,
Myelodysplasia, and
Transplantation
Lung Cancer
Lymphoma and
Plasma Cell Disorders
Melanoma/Skin Cancers
Other Cancer
NCI/CTEP Abstracts &
Activities:
DCTD/DCP Abstracts
The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute
(NCI), is designed to promote and support clinical trials of new cancer treatments, cancer
control and prevention strategies, quality-of-life issues during and after interventions, as
well as cancer imaging trials that target therapy, surveillance, and biomarkers of
therapeutic responses. An issue of this report will be distributed biannually in Summer
(post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium,
ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the
research presentations of the Cooperative Groups and the supporting activities of NCI
investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy
Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation
Research Program, and from the Division of Cancer Prevention.
Research Highlights in this Issue:
NSABP-B-18, NSABP-B-27: A meta-analysis including 12 randomized controlled trials
of neoadjuvant systemic therapy in breast cancer was conducted and showed:
• ypT0, ypN0: Absence of invasive cancer in the breast and axillary nodes, and
absence of ductal carcinoma in situ (DCIS) (13%)
• ypT0/is, ypN0: Absence of invasive cancer in the breast and axillary nodes; DCIS
is allowed (18%)
• ypT0/is: Absence of invasive cancer in the breast regardless of nodal involvement;
DCIS is allowed (22%)
The achievement of a pathologic CR was positively associated with more favorable
long-term outcomes, regardless of whether DCIS was present or absent. For consistency, a
standard pathologic CR definition was recommended for use in future trials, preferably
ypT0ypN0 or ypT0/isypN0.
Unfortunately, the magnitude of pathologic CR improvement predicting long-term
clinical benefit could not be established, raising questions as to the potential utility of pCR
as a surrogate endpoint for neoadjuvant clinical trials in breast cancer. On March 22, 2013,
the FDA is conducting a workshop to discuss the potential of pCR in drug development.
E2902: In older patients with relapsed/refractory acute myelogenous leukemia in
remission, administration of tipifarnib was found in an unplanned analysis to be associated
with improved survival at 10 months (70% with tipifarnib versus 48% with observation).
Interestingly the differences in relapse rate was not different between the treatment arms.
These findings may support clinical investigations of treatment strategies that do not
depend on maintaining a complete response but that do have clinical benefit with improved
survival.
Cooperative Group Abstracts
Breast Cancer
ACOSOG/Alliance
Boughey J, Suman V, Mittendorf E, Ahrendt G, Wilke L, Taback B, Leitch A, Flippo-Morton T, Byrd
D, Ollila D, Julian T, McLaughlin S, McCall L, Symmans W, Le-Petross H, Haffty B, Buchholz T, and
Hunt K: The role of sentinel lymph node surgery in patients presenting with node positive breast
cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071
trial. Cancer Res 2012; 72(Suppl 24): Abst. S2-1.
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S2-1?rss=1
Protocol(s): ACOSOG-Z1071
Ellis MJ, Suman V, McCall L, Luo R, Hoog J, Brink A, Watson M, Ma C, Unzeitig G, Pluard T,
Whitworth P, Babiera G, Guenther M, Dayao Z, Leitch M, Ota D, Olson J, Hunt K, and Allred C:
Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy Based on
2 to 4 week Ki67 level > 10%. Cancer Res 2012; 72(Suppl 24): Abst. PD07-01.
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/PD07-01?rss=1
Mittendorf E, Ballman K, McCall L, Hansen N, Lucci A, Gabram S, Urist M, Crow J, Hurd T, Hunt K,
and Giuliano A: Evaluation of the stage IB designation of the 7th edition of the AJCC staging system:
Biologic factors are more important. Cancer Res 2012; 72(Suppl 24): Abst. P1-01-06.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P1-01-06?sid=78e40e09-2cd5-4407-ad46b69fff5a7eba
CALGB/Alliance
Freedman R, Pitcher B, Keating N, Barry W, Ballman K, Kornblith A, Mandelblatt J, Kimmick G,
Hurria A, Winer E, Hudis C, Cohen H, and Muss H: Changes in Cognitive Function in Older Women
With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907.
Cancer Res 2012; 72(Suppl 24): Abst. P6-08-05.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P6-08-05
Protocol(s): CALGB-49907
Landis M, Yau C, Neumeister V, Rimm D, Esserman L, and Chang J: Multicenter I-SPY 1 TRIAL
(CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and
worse survival. Cancer Res 2012; 72(Suppl 24): Abst. P2-10-06.
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P2-10-06?rss=1
Protocol(s): CALGB-150007, CALGB-150012
Liu M, Pitcher B, Mardis E, Davies S, Snider J, Vickery T, Reed J, DeSchryver K, Singh B, Friedman
P, Gradishar W, Perez E, Martino S, Citron M, Norton L, Winer E, Hudis C, Perou C, Ellis M, and
Barry W: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant
anthracycline and taxane based chemotherapy. Cancer Res 2012; 72(Suppl 24): Abst. P2-10-01.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P2-10-01
Protocol(s): CLB-9741
NCI-Sponsored Groups Meetings Report
Winter 2013
2 of 20
Wolf D, Yau C, Magbanua M, Boudreau A, Davis S, Haqq C, Park J, Esserman L, and van't Veer L:
Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in
treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Cancer Res
2012; 72(Suppl 24): Abst. P2-05-01.
Other Participant(s): ACRIN
Protocol(s): ACRIN-6657, CALGB-150007, CALGB-150012
Wulfkuhle J, Wolf D, Gallagher R, Yau C, Calvert V, Espina V, Illi J, Wu Q, Boe M, Yan Y, Liotta L,
van't Veer L, Esserman L, and Petricoin E: Protein pathway activation mapping of the I-SPY 1 biopsy
specimens identifies new network focused drug targets for patients with triple negative tumors. Cancer
Res 2012; 72(Suppl 24): Abst. P3-04-01.
Wulfkuhle J, Yau C, Gallagher R, Wolf D, Calvert V, Espina V, Illi J, Wu Q, Boe M, Yan Y, Liotta L,
van't Veer L , Esserman L, and Petricoin E: Protein pathway activation mapping of I-SPY 1 biopsy
specimens identifies new network focused drug targets for patients with HR+/HER2– tumors. Cancer
Res 2012; 72(Suppl 24): Abst. P3-04-02.
ECOG
Miller KD, O'Neill A, Dang CT, Northfelt DW, Gradishar WJ, Sledge GW: Bevacizumab (B) in the
adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group
trial E5103. Cancer Res 2012; 72(Suppl 24): Abst. P5-17-01.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-17-01?sid=4a4625fa-5383-495e-976869ddb4a21da8
Other Participant(s): CTSU
Protocol(s): E5103
NCCTG/Alliance
Moreno-Aspitia A, Rowland, Jr. KM, Allred JB, Liu H, Stella PJ, Gross HM, Soori GS, Karlin NJ,
Perez EA: N0937 (Alliance): Preliminary Results of a Phase II Clinical Trial of Cisplatin and the
Novel Agent Brostallicin in Patients with Metastatic Triple Negative Breast Cancer (mTNBC). Cancer
Res 2012; 72(Suppl 24): Abst. P1-12-06.
http://www.abstracts2view.com/sabcs12/view.php?nu=SABCS12L_778
Protocol(s): NCCTG-N0937
Perez EA, Eckel-Passow JE, Ballman KV, Anderson SK, Thompson EA, Asmann YW, Jen J, Dueck
AC, Lingle WL, Sledge GW, Winer EP, Gralow J, Jenkins RB, Reinholz MM: Predictive Genomic
Markers To Chemotherapy and Adjuvant Trastuzumab Via Whole Genome Expression DASL
Profiling in the N9831 Adjuvant Study. San Antonio Breast Cancer Symposium (SABCS), San
Antonio, TX, Dec 2012. Abst. PD10-04.
Protocol(s): NCCTG N9831-ICSC
Winter 2013
3 of 20
Rimm D, Ballman KV, Cheng H, Vassilakopoulou M, Chen B, Gralow J, Hudis C, Davidson NE,
Psyrri A, Fountzilas G, Perez EA: EGFR Expression Measured by Quantitative Immunofluorescense Is
Associated with Decreased Benefit from Trastuzumab in the Adjuvant Setting in the NCCTG
(Alliance) N9831 Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec
2012. Abst. S5-4.
Protocol(s): NCCTG N9831-ICSC
NCIC Clinical Trials Group
Burnell MJ, Shepherd L, Gelmon K, Bramwell V, Walley B, Vandenberg E, Chalchal H, Pritchard K,
Whelan TJ, Albain K, Perez EA, Rugo H, O'Brien PS, Chapman J-A, Levine M: randomized trial of
CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with
node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse
free survival analysis. Cancer Res 2012; 72(Suppl 24): Abst. P1-13-01.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P1-13-01?sid=ef4aca18-18e3-45bc-9a8c4537acb2160c
Protocol(s): NCIC-MA.21
Higgins MJ, Chapman J, Ingle J, Sledge G, Budd GT, Ellis MJ, Pritchard KI, Clemons M, Badovinac
TB, Han L, Gelmon K, Rabaglio M, Elliott C, Shepherd LE, Goss PE: Effect of aspirin (ASP) or
celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant
exemestane or anastrozole: NCIC CTG MA.27. Cancer Res 2012; 72(Suppl 24): Abst. P2-13-02.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P2-13-02?sid=e455469a-7430-4ba5-b431ec2faa94cb69
Protocol(s): NCIC-MA.27
NSABP
Aebi S, Gelber S, Láng I, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Mamounas EP, Geyer
CE Jr, Maibach R, Gelber RD, Wolmark N, Wapnir I: Chemotherapy prolongs survival for isolated
local or regional recurrence of breast cancer: The CALOR Trial (Chemotherapy as Adjuvant for
LOcally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Cancer Res 2012;
72(Suppl 24): Abst. S3-2.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S3-2?sid=8a0a9401-71f0-4506-ba86-c712040e41a8
Protocol(s): NSABP-B-37
Cobleigh MA, Anderson SJ, Julian TB, Siziopikou KP, Arthur DW, Rabinovitch R, Zheng P,
Mamounas EP, Wolmark N: NSABP B-43: A phase III clinical trial to compare trastuzumab given
concurrently with radiation therapy to RT alone for women with HER2+ DCIS resected by
lumpectomy. Cancer Res 2012; 72(Suppl 24): Abst. OT1-02-01.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT1-2-01?sid=c9ad9cb6-2528-4c5f-8e79ef177a3f91a2
Winter 2013
4 of 20
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni
L, Valagussa P, Zujewski JA, Justice R, Loibl S, Wickerham L, Bogaerts J, Baselga J, Perou C,
Blumenthal G, Blohmer J, Mamounas E, Bergh J, Semiglazov V, Prowell T, Eidtmann H, Paik S,
Piccart M, Sridhara R, Fasching P, Swain SM, Slaets L, Tang S, Gerber B, Geyer C, Pazdur R, Ditsch
N, Rastogi P, Eiermann W, von Mincwitz G: Meta-analysis results from the collaborative trials in
neoadjuvant breast cancer (CTNeoBC). Cancer Res 2012; 72(Suppl 24): Abst. S1-11.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S1-11?sid=2bed17a3-2774-42fd-a123073f4ebde791
Protocol(s): NSABP-B-18, NSABP-B-27
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong J-H, Kim S-R, Butler SM, Jamshidian F,
Cherbavaz DB, Shak S, Julian T, Lembersky B, Wickerham DL, Costantino JP, Wolmark N:
Prognostic impact of the 21-gene Recurrence Score on disease-free and overall survival of nodepositive, ER-positive breast cancer patients treated with adjuvant chemotherapy: Results from NSABP
B-28. J Clin Oncol 2012; 30(Suppl 27): Abst. 1.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=125&abstractID=102893
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong J-H, Kim S-R, Butler SM, Jamshidian F,
Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark
N: Association between the 21-gene Recurrence Score and benefit from adjuvant paclitaxel in nodepositive, ER-positive breast cancer patients: Results from NSABP B-28. Cancer Res 2012; 72(Suppl
24): Abst. S1-10.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S1-10?sid=eff18f6e-c79a-4034-ab62-8e281a134195
Romond E, Suman VJ, Jeong J-H, Sledge, Jr. GW, Geyer, Jr. CE, Martino S, Rastogi P, Gralow J,
Swain SM, Winer E, Colon-Otero G, Hudis C, Paik S, Davidson N, Mamounas EP, Zujewski JA,
Wolmark N, Perez EA: Trastuzumab Plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer:
Final Planned Joint Analysis of Overall Survival (OS) from NSABP B-31 and NCCTG N9831. San
Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2012. Abst. S5-5.
Other Participant(s): NCCTG/Alliance
Protocol(s): NCCTG N9831-ICSC, NSABP-B-31
Wapnir IL, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas EP,
Geyer CE, Maibach R, Gelber RD, Wolmark N, Aebi S: Patterns of locoregional failure in the CALOR
(Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer) trial. Cancer Res 2012; 72(Suppl
24): Abst. P6-07-06.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P6-07-06?sid=8a0a9401-71f0-4506-ba86c712040e41a8
Winter 2013
5 of 20
RTOG
McCormick B, Moughan J, Hudis C, Kuerer H, Rakovitch E, Smith B, Sneige N, Shah A, Germain I
and White J: Low-risk Breast Ductal Carcinoma In Situ (DCIS): Results From the Radiation Therapy
Oncology Group 9804 Phase 3 Trial. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S5.
http://www.redjournal.org/article/S0360-3016(12)00955-8/fulltext
Protocol(s): RTOG-9804
SWOG
Chavez-MacGregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA,
Schott AF, Paik S, Lew DL, Bandos H, Hortobagyi GN: Phase III randomized, placebo-controlled
clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients
with high-risk, hormone receptor-positive and HER2-negative breast cancer: SWOG/NSABP S1207.
Cancer Res 2012; 72(Suppl 24): Abst. OT2-2-04.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT2-2-04?sid=f0efaef4-ce85-4d8d-8f6174bf93a69880
Other Participant(s): CTSU, NSABP
Protocol(s): S1207
Greenlee H, Crew KD, Capodice J, Jeffres A, Awad D, Unger J, Lew D, Hartline JA, Hansen L,
Hershman DL: Methods for standardizing true and sham acupuncture in a multicenter randomized trial
to reduce joint symptoms related to aromatase inhibitors in women with early stage breast cancer
(SWOG 1200). Society for Integrative Oncology, Albuquerque, NM, Oct 2012.
http://www.integrativeonc.org/index.php/component/option,com_dropbox/Itemid,200/view,dropbox/
Protocol(s): SWOG-S1200
CNS Cancer
RTOG
Beitler JJ, Zhang Q, Fu K, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J and Ang
KK: RTOG 90-03: Final Report. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S6.
http://www.redjournal.org/article/S0360-3016%2812%2900966-2/fulltext
Protocol(s): RTOG-90-03
Brown P, Shook S, Laack N, Choucair A, Wefel J, Meyers C, Watkins-Bruner D: Memantine for the
Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiation Therapy (WBRT):
First Report of RTOG 0614, a Placebo-controlled, Double-blind, Randomized Trial. Int J Radiat Oncol
Biol Phys 2012; 84(3 Suppl.): Pg. S1-S2.
Cairncross G, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Mehta M,
Curran W: IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic
Oligodendroglioma (RTOG 9402). Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S5.
Other Participant(s): NCCTG/Alliance
Protocol(s): INT-0149
Winter 2013
6 of 20
Chakravarti A, Wang M, Aldape K, Sulman E, Bredel M, Hegi M, Gilbert M, Curran W, WernerWasik M and Mehta M: A Revised RTOG Recursive Partitioning Analysis (RPA) Model for
Glioblastoma Based Upon Multiplatform Biomarker Profiles. Int J Radiat Oncol Biol Phys 2012; 84(3
Suppl.): Pg. S4-S5.
Robins HI, Wang M, Gilbert M, Chakravarti A, Grimm S, Penas-Prado M, Chaudhary R, Anderson P,
Elinzano H, Gilbert R and Mehta M: Phase I Results from RTOG 0929, a Randomized Phase I/II
Study of ABT-888 (veliparib) in Combination with Temozolomide (TMZ) in Recurrent, TMZResistant Glioblastoma. Neuro-Onocology 2012; 14(suppl 6): Pg. vi65-vi85, No-14.
http://neuro-oncology.oxfordjournals.org/content/14/suppl_6/vi65.full
Vogelbaum M, Wang M, Peereboom D, Macdonald D, Giannini C, Suh J, Jenkins R, Laack N,
Brachman D, Shrieve DC, Souhami L and Mehta M: RTOG 0131: Phase II Trial of Pre-Irradiation and
Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and
Mixed Anaplastic Oligodendrogliomas – Updated Survival and Progression Free Survival Analysis.
Neuro-Onocology 2012; 14(suppl 6): Pg. vi65-vi85, No-56.
Wefel J, Shook S, Brown P, Laack N, Khuntia D, Meyers C, Choucair A, Fox S, Suh J, Roberge D,
Kavadi V, Bentzen S, Mehta M and Watkins Bruner D: Memantine for the Prevention of Cognitive
Dysfunction in Patients Receiving Whole-Brain Radiotherapy (WBRT): First Report of RTOG 0614, a
Placebo-Controlled, Double-Blind, Randomized Trial. Neuro-Onocology 2012; 14(suppl 6): Pg. vi61vi64, NC-08.
Gastrointestinal Cancer
NCCTG/Alliance
Sloan JA, Shi, Q, Lee A, Diasio R, Pavey E, Sargent D, Goldberg R, Mahoney M, Alberts S:
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients
(pts) prior to adjuvant treatment (N0147). International Society for Quality of Life Research
(ISOQOL), Budapest, Hungary, Oct 2012. Abst. 302.2.
http://www.isoqol.org/2012conference/final-program.pdf
Protocol(s): N0147
NSABP
O'Connell MJ, Lee M, Lopatin M, Yothers G, Clark-Langone K, Millward C, Paik S, Sharif S, Shak S,
Wolmark N: The 12-gene colon cancer recurrence score predicts recurrence in stage II and III colon
cancer patients treated with 5FU/LV and 5FU/LV+oxaliplatin: Validation in NSABP C-07. Annals of
Oncology (Oxford University Press) 2012; 23(Suppl 9): Abst. 532PD.
http://annonc.oxfordjournals.org/content/23/suppl_9/ix178.full.pdf
Protocol(s): NSABP-C-07
Winter 2013
7 of 20
Pogue-Geile KL, Tanaka N, Gavin P, Yothers G, Colangelo L, Kim C, Kim S-R, Fumagalli D,
Taniyama Y, Sharif S, O'Connell M, Wolmark N, Paik S: DNA mismatch repair deficiency and benefit
from adjuvant bevacizumab in NSABP C-08: Molecular profiling results. J Clin Oncol 2012; 30(Suppl
30): Abst. 55.
Protocol(s): NSABP-C-08
RTOG
Doll C, Moughan J, Klimowicz A, Lees-Miller S, Ajani J, Crane C, Kachnic L, Okawara G, Guha A
and Magliocco A: The Significance of Coexpression of Epidermal Growth Factor Receptor (EGFR)
and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiation Therapy:
An Analysis of RTOG 98-11. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S145.
Raponi M, Boeck S, Isaacson J, Ranger Moore J, Clements J, Richardson B, Towne P, Ormanns S,
Kirchner T, Regine W, Bradley F, Winter K, Rolfe L, Allen A, Andersson R, Heinemann V and Dicker
A: Development of a rabbit monoclonal antibody for determining hENT1 status and predicting
response to gemcitabine in pancreatic ductal adenocarcinoma. European Congress of Pathology,
Lisboa, Portugal, Sep 2012. Abst. OFP-04.
http://www1.esp-congress.org/ecp2012/guest/AbstractView?ABSID=3711
Williams T, George A, Regine W, Thomas D, Schaefer P, Safran H, Small W, Guha C and Ben-Josef
E: Caveolin-1 Expression Correlates With Outcomes in Pancreatic Ductal Carcinoma: A Secondary
Analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S26.
Genitourinary Cancer
RTOG
Bruner D, Hunt D, Michalski J, Bosch W, Yan Y, Galvin J, Bahary J, Morton G, Parliament M and
Sandler H: Value Added of Patient-Reported Data to Clinician Reported Toxicity Data: Preliminary
Analysis of 3DCRT vs IMRT on RTOG 0126 Prostate Cancer Trial High Dose Arm. International
Society for Quality of Life Research (ISOQOL), Budapest, Hungary, Oct 2012. Abst. 102.1.
http://www.isoqol.org/2012conference/final-program.pdf
Hamstra D, Hunt D, Grignon D, Hanks G, Peters C, Rosenthal S, Lock M, Zeitzer K, Souhami L and
Sandler H: Gleason Pattern 5 is Associated With an Increased Risk for Metastasis Following Androgen
Deprivation Therapy (ADT) and Radiation: An Analysis of RTOG 9202 and 9902. Int J Radiat Oncol
Biol Phys 2012; 84(3 Suppl.): Pg. S91-S92.
Protocol(s): RTOG-92-02, RTOG-99-02
Winter 2013
8 of 20
Lawton C, Shook S, Smith M, Tripp P, Shah A, Martin A-G, Kim H, Tai P, Nabid A and Kachnic L:
RTOG Protocol 05-18: A Phase III Randomized Trial to Evaluate the Efficacy of Zoledronic Acid for
the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy (RT)
and Long-term Luteinizing Hormone-releasing Hormone (LHRH) Agonist for High-grade and/or
Locally Advanced Prostate Cancer. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S369.
Mak K, Yan Y, Smith M, Hanks G, Brereton H, Bauman G, Rosenthal S, Zeitzer K, Sandler H and
Efstathiou J: Diabetes and Cardiovascular Mortality in Men With Locally Advanced Prostate Cancer:
Updated Analysis From RTOG 92-02. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S94.
http://www.redjournal.org/article/S0360-3016%2812%2901190-X/fulltext
Mak R, Hunt D, Shipley W, Efstathiou J, Yan Y, Tester W, Hagan M, Kaufman D, Heney N and
Zietman A: Long-term Outcomes After Bladder Preserving Combined Modality Therapy for Muscleinvasive Bladder Cancer: A Pooled Analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. Int J
Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S121.
Protocol(s): RTOG-0233, RTOG-88-02, RTOG-89-03, RTOG-95-06, RTOG-97-06, RTOG-9906
Mak R, Hunt D, Shipley W, Jones C, Lukka H, Bahary J-P, Souhami L, Husain S, Efstathiou J and
Sandler H: Acute and Late Urinary Toxicity After Radiation Therapy in Men With and Without an
Intact Prostate Gland: A Secondary Analysis of RTOG 9408 and 9601 Suggesting This Toxicity is Not
Due to Bladder Injury. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S14.
Protocol(s): RTOG-94-08, RTOG-96-01
Michalski J, Yan Y, Tucker S, Winter K, Bosch W, Galvin J, Bahary J, Morton G, Xiao Y and Sandler
H: Dose Volume Analysis of Grade 2+ Late GI Toxicity on RTOG 0126 After High-dose 3DCRT or
IMRT. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S14-S15.
http://www.redjournal.org/article/S0360-3016(12)00987-X/fulltext
SWOG
Goldkorn A, Vogelzang NJ, Ely B, Fink LM, Quinn DI, Tangen CM, Tai Y-C, Twardowski P, Van
Veldhuizen PJ, Agarwal N, Carducci MA, Monk P, Garzotto M, Mack PC, Lara P, Higano CS,
Hussain M, Cote RJ, Thompson IM: Circulating tumor cell (CTC) counts and CTC telomerase activity
(TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without
atrasentan for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012; 30(Suppl
30): Abst. 1.
Protocol(s): S0421
Winter 2013
9 of 20
Gynecologic Cancer
RTOG
Hashem R, Winter K, Ruo R, Portelance L, Jhingran A, Demas W, Jacobson G and Gaffney D:
Defining the Impact of the Use of Oral Contrast in Pelvic Intensity Modulated Radiation Therapy
(IMRT) – An RTOG 0418 Secondary Analysis. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg.
S18-S19.
Schefter T, Winter K, Kwon J, Stuhr K, Balaraj K, Yaremo B, Small Jr W, Sause W and Gaffney D:
RTOG 0417: Efficacy of Bevacizumab in Combination With Definitive Radiation Therapy and
Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma. Int J
Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S17.
Head and Neck Cancer
NCCTG/Alliance
Miller RC, Leenstra J, Qin R, Martenson JA, Dornfeld KJ, Bearden JD, Puri D, Stella PJ, Foote RL,
Loprinzi CL: N09C6 (Alliance) - A Phase 3, Randomized Double-Blind Study of Doxepin Rinse
Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck
Radiation Therapy With or Without Chemotherapy. Int J Radiat Oncol Biol Phys 2012; 85(1): Pg. 21.
http://download.journals.elsevierhealth.com/pdfs/journals/0360-3016/PIIS0360301612037728.pdf
Protocol(s): NCCTG-N09C6
RTOG
Grossman C, Localio AR, Langer C, Wheeler R, Lin A, Zhang E, Ang K and Kanetsky P: Host, tumor,
and treatment predictors of grade 4-5 acute toxicity during reirradiation for locoregionally recurrent
head and neck cancer (HNC). Radiation Research Society, San Juan, Puerto Rico, Sep 2012. Abst.
PS7-43.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3021&sKey=98fd346d-1d0c-475f-9c13-6c888c99f248&cKey=6ebf6508-65594acf-8718-4b85798b0db3&mKey={1514526B-FDA6-42BC-948B-C58023F5A94F}
Machtay M, Zhang Q, Suntharalingam M, Hershock D, Lustig R, Nabid A, Doncals D, Prichard H,
Shenouda G and Ang K: Long-term Outcomes from RTOG 99-03: Radiation Therapy With or Without
Erythropoietin for Anemic Head-and-Neck Cancer Patients. Int J Radiat Oncol Biol Phys 2012; 84(3
Suppl.): Pg. S21.
Winter 2013
10 of 20
Leukemia, Myelodysplasia, and Transplantation
CALGB/Alliance
Blum W, Sanford B, Klisovic RB, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE,
Wetzler M, Hoke E, Bloomfield CD, Geyer S, Marcucci G, Stone RM, and Larson RA: Maintenance
Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission:
A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). Blood 2012; 120(21):
Abst. 44..
http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/44
Devine SM, Owzar K, Blum W, DeAngelo D, Stone RM, Hsu JW, Champlin RE, Chen Y-BA, Vij R,
Slack JL, Soiffer RJ, Larson RA, Shea TC, Hars V, Bennett E, Spangle S, Giralt SA, Carter SL,
Horowitz MM, Linker C, and Alyea EP, III: A Phase II Study of Allogeneic Transplantation for Older
Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen:
Results From CALGB 100103/BMT CTN 0502. Blood 2012; 120(21): Abst. 230.
Wetzler M, Watson D, Stock W, Owzar K, Koval G, Hoke E, McCarty JM, Blum W, Powell BL,
Marcucci G, Bloomfield CD, Linker C, and Larson RA: Autologous Transplantation for Philadelphia
Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic
Transplantation - Results of CALGB 10001 (Alliance). Blood 2012; 120(21): Abst. 816.
Whitman S, Kohlschmidt J, Maharry K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mrozek K,
Mendler JH, Eisfeld A-K, Volinia S, Powell BL, Carter TH, Kolitz JE, Stone RM, Park I-K, Caligiuri
MA, Marcucci G, and Bloomfield CD: Adverse Prognostic Impact of GAS6 Expression in De Novo
Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance).
Blood 2012; 120(21): Abst. 1293.
Protocol(s): CALGB-20202, CALGB-8461, CALGB-9665
ECOG
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C,
Parekh SS, Pellagatti A, Boultwood J, Paietta EM, Ketterling RP, Cripe LD, Fernandez HF, Greenberg
PL, Rowe JM, Tallman MS, Steidl C, Mitsiades CS, Verma AK, Steidl UG: Parallel transcriptional
analysis of multiple stem and progenitor populations identifies novel commonly dysregulated and
functionally relevant targets in AML. Blood 2012; 120(21): Abst. 1875.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/1875?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=1875&searchid
=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT&eaf
Protocol(s): E1900, E2995, E3999
Winter 2013
11 of 20
Cesano A, Willman C, Kopecky K, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer D,
Marimpietri C, Hackett J, Shi J, Paietta EM, Tallman MS, Cripe LD, Atwater S, Appelbaum FR,
Radich JP: Single-cell network profiling (SCNP)-based classifier to predict response to induction
therapy in elderly patients with acute myeloid leukemia (AML): Validation in two independent sample
sets from ECOG and SWOG trials. Blood 2012; 120(21): Abst. 2489.
=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
Other Participant(s): SWOG
Protocol(s): E3999, S0112, S0301, S9031-S9126-S9333-S9500
DiNardo C, Levine RL, Propert KJ, Loren AW, Paietta EM, Sun Z, Straley KS, Yen K, Patel JP,
Agresta S, abdel-Wahab O, Perl AE, Fernandez HF, Margolis D, Tallman MS, Luger SM, Carroll MP:
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in
acute myeloid leukemia. Blood 2012; 120(21): Abst. 2481.
=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Protocol(s): E1900
Geng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner JW, Chang BH, Titz B, Buchner M, Hurtz C,
Graber T, Druker BJ, Paietta EM, Melnick AM, Willman CL, Carroll WL, Muschen M: Integrative
analysis of ikaros-dependent changes of transcriptional regulation and tyrosine phosphorylation events
in Ph+ ALL. Blood 2012; 120(21): Abst. 528.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/528?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=+528&searchid=
1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
Protocol(s): E2993
Laurie CC, Laurie CA, Fridley B, Carlson E, Smoley S, Flinn IW, Tallman MS, Paietta EM,
Weinshilboum R, Kay NE, Shanafelt TD: Clonal chromosomal anomalies similar to CLL and other
hematologic malignancies can be found in "normal" individuals. Blood 2012; 120(21): Abst. 873.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/873?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=873&searchid=1
&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Other Participant(s): CALGB/Alliance, SWOG
Protocol(s): E2997
Luger SM, Zickl L, Paietta EM, Ketterling RP, Lazarus HM, Rybka WB, Litzow MR, Rowe JM,
Larson RA, Tallman MS: R115777(tipifarnib) improves early survival when used as maintenance
therapy for elderly or relapsed/refractory patients with acute myelogenous leukemia in remission.
Blood 2012; 120(21): Abst. 676.
Protocol(s): E2902
Marks DI, Moorman AV, Chilton LA, Paietta EM, Dewald G, Fielding AK, Goldstone AH, Litzow
MR, Luger SM, McMillan AK, Rowe JM, Tallman MS, Lazarus HM: Biology and outcome of 85
adults with acute lymphoblastic leukemia (ALL) with t(4;11)/MLL-AF4 treated on the UKALL
XII/ECOG 2993 study. Blood 2012; 120(21): Abst. 663.
Protocol(s): E2993
Winter 2013
12 of 20
Van Vlierberghe P, Ambesi-Impiombato A, Rigo I, Hadler M, Paietta EM, Wiernik PH, Rowe JM,
Rue M, Ferrando AA: Prognostic relevance of integrated genetic profiling in adult T-cell acute
lymphoblastic leukemia. Blood 2012; 120(21): Abst. 294.
Protocol(s): E2993
Watts JM, Zickl L, Litzow MR, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D,
Paietta EM, Rowe JM, Tallman MS: Practically all patients with acute myeloid leukemia (AML) in
continuous complete remission for 3 years or more are cured of their disease: The ECOG experience.
Blood 2012; 120(21): Abst. 132.
Protocol(s): E1900, E3489, EST-3483
NCCTG/Alliance
Ding W, Shanafelt TD, Lesnick C, Sassoon T, Secreto C, Erlichman C, Leis J, Call T, Bowen D,
Kumar SK, Kay N: Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the
Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated
Cytokine Production. Blood 2012; 120(21): Abst. 3928.
OTHER
Muffly L, Stock W, Breitenbach A, Mulkey F, Luger S, Advani A, Parker E, Foster MC, Liedtke M,
Garcia R, Coffan K, Sipin-Sayno J, McNeer J, Tallman M, Appelbaum F, Stone R, Larson R: Who
Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline
Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for
Acute Lymphoblastic Leukemia (ALL). Blood 2012; 120(21): Abst. 3535.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3535?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=swog&searchid
Other Participant(s): CALGB/Alliance, ECOG, SWOG
Protocol(s): C10403
SWOG
Advani A, McDonough S, Coutre SE, Wood B, Radich J, Mims M, O’Donnell M, Elkins S, Becker
MW, Othus M, Appelbaum F: Southwest Oncology Group Study S0910: A Phase 2 Trial of
Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia. Blood
2012; 120(21): Abst. 2603.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2603?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=s0910&searchid
Protocol(s): S0910
Winter 2013
13 of 20
Nand S, Othus M, Godwin J, Willman C, Norwood T, Erba H, Howard D, Coutre S, Appelbaum F: A
Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As
Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated
Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. Blood 2012;
120(21): Abst. 3584.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3584?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=NAND&searchi
d=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
Protocol(s): S0703
Ostronoff F, Othus M, Meshinchi S, Appelbaum F, Estey E: A Scoring System for Prediction of FLT3ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 2012; 120(21):
Abst. 2590.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2590?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=FLT3ITD+positi
vity&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
Protocol(s): S0106, S9031-S9126-S9333-S9500
Othus M, Kantarjian K, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S,
Appelbaum F, Estey E: Declining Rates of Treatment-Related Mortality in Patients with Newly
Diagnosed Acute Myeloid Leukemia (AML) Given "Intensive" Induction Regimens: A Report From
the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). Blood 2012;
120(21): Abst. 129.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/129?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=
Protocol(s): S0106, S0112, S8600-S9031-S9333-A, S9031-S9126-S9333-S9500, S9918
Walter R, Othus M, Burnett AK, Lowenberg A, Kantarjian H, Ossenkoppele G, Hills RK, van
Montfort K, Ravandi F, Pierce S, Appelbaum F, Estey E: Prognostic Significance of the FrenchAmerican-British (FAB) Morphologic Subclassification of "Acute Myeloid Leukemia, Not Otherwise
Specified" in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From
HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. Blood 2012; 120(21): Abst. 540.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/540?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=
Protocol(s): S0106, S0112, S8600-S9031-S9333-A, S9031-S9126-S9333-S9500
Lung Cancer
CALGB/Alliance
Janne P, Shepherd F, Domerg C, Le Teuff G, Kratzke R, Hainaut P, Pignon J, Rosell R, Soria J, and
Tsao M: Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with
P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study. Annals of
Oncology (Oxford University Press) 2012; 23(Suppl 9): Abst. 1700.
http://annonc.oxfordjournals.org/content/23/suppl_9/ix73.abstract?sid=f3d4d421-30a0-497a-8e9e-bb1b91236dc0
Lilenbaum R, Samuels M, Kong F, Wang X, Janne P, Masters G, Bogart J, Bradley J, and Vokes E: A
Phase II Study Of Induction Chemotherapy Followed By Thoracic Radiotherapy (TRT) And Erlotinib
In Poor-risk Stage III Non-small Cell Lung Cancer (NSCLC): Initial Results Of CALGB 30605 And
RTOG 0972. Journal of Thoracic Oncology 2012; 7(15): Abst. 153.
http://journals.lww.com/jto/Fulltext/2012/09004/Abstracts.5.aspx
Winter 2013
14 of 20
Salgia R, Nallasura V, Pang H, Rolle C, Richards W, Hodgson L, Arif Q, Husain A, Kratzke R, and
Vokes E: An Interim Report of CALGB 150607: Expression and Mutational Status of c-MET, HGF,
EGFR, KRAS, p53, c-CBL, and E-cadherin in Resected Lung Adenocarcinoma Specimens. Journal of
Thoracic Oncology 2012; 7(15): Abst. 190.
http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2979&sKey=dba4b6e6-0dfb-46f2-9127-9a468d12afae&cKey=8b76e413601a-49a8-a400-ae1bc923bb75&mKey={E968B2E9-DA03-409D-9B81-7EFE158EB9C1}
ECOG
Gerber DE, Dahlberg SE, Sandler AB, Perry MC, Schiller JH, Brahmer JR, Johnson DH: Association
between baseline baseline tumor diameters and overall survival in patients with advanced non-small
cell lung cancer (NSCLC). Journal of Thoracic Oncology 2012; 7(15): Abst. 116.
http://journals.lww.com/jto/Fulltext/2012/09004/Abstracts.5.aspx
Protocol(s): E4599
NCCTG/Alliance
Schild S, Hillman S, Graham D, Vora S, Garces Y, Olivier K, Kugler J, Ross H, Molina J, Adjei A:
Long-term Survival Of Patients(pts) Treated With High-dose Radiotherapy(rt) & Concurrent
Chemotherapy For Unresectable Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic
Oncology 2012; 7(15): Abst. 158.
http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2979&sKey=dba4b6e6-0dfb-46f2-9127-9a468d12afae&cKey=39511b25c242-4c7a-ad9b-4c76c3843769&mKey={E968B2E9-DA03-409D-9B81-7EFE158EB9C1}
RTOG
Chen W, Cui Y, Kong F, Machtay M, Videtic G, Loo B, Gore E, Galvin J, Yu Y and Xiao Y:
Quantitative Evaluation of Impact Upon Tumor Control Probability (TCP) From Quality Assurance
Criteria for Non-small Cell Lung Cancer From RTOG 1106 Study. Int J Radiat Oncol Biol Phys 2012;
84(3 Suppl.): Pg. S601.
Chen W, Cui Y, Kong F, Machtay M, Videtic G, Loo B, Gore E, Galvin J, Yu Y and Xiao Y: Is
Recontouring Organs-at-Risk (OAR) for Adaptive Radiation Therapy Plans for Locally Advanced
Lung Cancer Necessary? A Preactivation Analysis From Radiation Therapy Oncology Group (RTOG)
1106. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S602.
Cui Y, Chen W, Appenzoller L, Beatty R, Maxim P, Ritter T, Sohn J, Higgins J, Yu Y, Kong F, Galvin
J and Xiao Y: Can Use of an Atlas Decrease Contouring Variability in Non-small Cell Lung Cancer
Radiation Therapy? Analysis of the RTOG 1106 Preclinical Trial Planning Study. Int J Radiat Oncol
Biol Phys 2012; 84(3 Suppl.): Pg. S573.
Winter 2013
15 of 20
Gore E, Paulus R, Wong S, Sun A, Videtic G, Dutta M, Suntharalingam M, Chen Y, Gaspar L and
Choy H: Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with
Locally Advanced Non-small Cell Lung Cancer -- An Updated Analysis of RTOG 0214. Int J Radiat
Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S103.
Gore E, Paulus R, Wong S, Sun A, Videtic G, Dutta S, Suntharalingam M, Chen Y, Gaspar L and
Choy H: Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with
Locally Advanced Non-small-cell Lung Cancer: Updated Analysis of RTOG 0214. Journal of Thoracic
Oncology 2012; 7(15): Abst. 5.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=af961e0d-edd2-4b48-a08a-86579c4faf1a&cKey=d38a7954-1a2e-4fcd-858b7981ef3f5f1c&mKey=%7bE968B2E9-DA03-409D-9B81-7EFE158EB9C1%7d
Matuszak M, Xiao Y, Presley J, Bosch W, Ten Haken R, Galvin J, Werner-Wasik M, Machtay M,
Bradley J and Fong F: The Importance of Dry Run Credentialing for RTOG 1106/ACRIN 6697: A
Trial of Individualized Adaptive Radiation Therapy for Patients with Locally Advanced Non-small
Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S26-S27.
Other Participant(s): ACRIN
Stanic S, Paulus R, Timmerman B, Michalski J, Barriger R, Bezjak A, Videtic G and Bradley J: No
Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy
(SBRT) Among Medically Inoperable Patients With Early Stage Peripheral Non-small Cell Lung
Cancer: An Analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 2012; 84(3 Suppl.): Pg. S48.
SWOG
Thomas CR, Moon J, Gaspar L, Raben D, Fitzgerald TJ, Wozniak A, Kelly K, Mack P, Pandya KJ,
Gandara DR: Initial Cooperative Group Experience of Bevacizumab (Bev) Plus Concomitant
Chemoradiotherapy (CRT) in Patients with Inoperable Locally Advanced Stage III Non-Small Cell
Lung Cancer (LA-NSCLC): Preliminary Results of S0533. Journal of Thoracic Oncology 2012; 7(15):
Abst. 7.
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=af961e0d-edd2-4b48-a08a-86579c4faf1a&cKey=ed6da053-e083-4df9-ab0c51cd3210ea4f&mKey={E968B2E9-DA03-409D-9B81-7EFE158EB9C1}
Protocol(s): S0533
Thomas CR, Moon J, Gaspar L, Raben D, Fitzgerald TJ, Wozniak A, Kelly K, Mack P, Pandya KJ,
Gandara DR: Initial Cooperative Group Experience of Bevacizumab (Bev) Plus Concomitant
Chemoradiation Therapy (CRT) in Patients With Inoperable Locally Advanced Stage III Non-small
Cell Lung Cancer (LA-NSCLC): Preliminary Results of S0533. Int J Radiat Oncol Biol Phys 2012;
84(3 Suppl.): Pg. S156.
Protocol(s): S0533
Winter 2013
16 of 20
Lymphoma and Plasma Cell Disorders
CALGB/Alliance
Morrison VA, Jung S-H, Johnson J, LaCasce A, Blum KA, Bartlett NL, and Cheson BD: Salvage
Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial
Results of a Phase II Trial (Alliance/CALGB 50501). Blood 2012; 120(21): Abst. 3696.
Rubenstein JL, Hsi ED, Johnson JL, Jung S-H, Grant B, Cheson BD, and Kaplan LD: BCL6
Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS
Lymphoma: Final Report of CALGB 50202 (Alliance). Blood 2012; 120(21): Abst. 301.
ECOG
Habermann TM, Hong F, Morrison VA, Dakhil SR, Weick JK, Frankel SR, Gascoyne RD, Fisher RI,
Cheson BD, Weller E, Kahl BS, Peterson BA, Hochster HS, Horning SJ: Differences in outcomes in
males and females with diffuse large B-cell lymphoma with induction rituximab and follicular
lymphoma treated with maintenance rituximab. Blood 2012; 120(21): Abst. 3705.
Protocol(s): E1496, E4494
Kahl BS, Li H, Smith MR, Gascoyne RD, Yang DT, Paietta EM, Advani RH, Horning SJ: Mature
results from E1405 - A phase II study of VcR-CVAD with maintenance rituximab for previously
untreated mantle cell lymphoma. Blood 2012; 120(21): Abst. 153.
Protocol(s): E1405
Lonial S, Jacobus S, Weiss M, Fonseca R, Dhodapkar MV, Rajkumar S. V: Phase II trial of initial
safety and toxicity prior to the phase III trial of lenalidomide versus observation alone in patients with
asymptomatic high-risk smoldering multiple myeloma (E3A06): A trial coordinated by the Eastern
Cooperative Oncology Group. Blood 2012; 120(21): Abst. 4079.
Protocol(s): E3A06
Swinnen LJ, Li H, Quon A, Gascoyne RD, Ranheim E, Habermann TM, Advani RH, Kahl BS,
Horning SJ: Response-adapted therapy for diffuse large b-cell non-Hodgkin's lymphoma (DLBCL)
based on early [18F] FDG-PET scanning: An Eastern Cooperative group study (E3404). Blood 2012;
120(21): Abst. 687.
Protocol(s): E3404
Winter 2013
17 of 20
Wagner LI, Zhao F, Williams ME, Gascoyne RD, Krauss JC, Cella D, Horning SJ, Kahl BS: Quality
of life results from Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized
phase III study comparing two different rituximab dosing strategies for low indolent non-Hodgkin's
lymphoma. Blood 2012; 120(21): Abst. 235.
Protocol(s): E4402
Weiss M, Jacobus S, Abonour R, Anderson KC, Barlogie B, Callander NS, Gorak EJ, Kane RC, Katz
MS, Matous JV, Mills GM, Orlowski RZ, Rajkumar S. V, Richardson PG,, Little RF, Gertz MA,
Munshi NC: Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple
Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials. Blood
2012; 120(21): Abst. 3165.
Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H, Advani RH, Kahl BS, Horning
SJ: A phase II trial of R-CHOP followed by zevalin radioimmunotherapy for patients with previously
untreated stages I and II CD20+ diffuse large cell non-Hodgkin's lymphoma: An Eastern Cooperative
Oncology Group study (E3402). Blood 2012; 120(21): Abst. 2687.
Protocol(s): E3402
NCCTG/Alliance
Inwards D, Fishkin P, LaPlant B, Drake M, Kurtin P, Nikcevich D, Wender D, Behrens R, Witzig T:
Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell
Lymphoma. Blood 2012; 120(21): Abst. 3661.
Protocol(s): NCCTG-N078D
Maurer MJ, Ghesquieres H, Witzig TE, Thompson CA, Micallef IN, Macon WR, Syrbu SI, Kurtin P,
Allmer C, Gargi T, Nicolas-Virelizier E, Sebban C, Slager S, Habermann T, Link BK, Cerhan JR:
Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who
Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival
Similar to That of the General Population. Blood 2012; 120(21): Abst. 1540.
Protocol(s): N0489
Winter 2013
18 of 20
NCIC Clinical Trials Group
Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz M, Borchmann P,
Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dorken B, Pearcey RG, Diehl V, Horning SJ,
Eich HT, Engert A, Meyer RM: Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An
Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11
Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD
Alone. Blood 2012; 120(21): Abst. 548.
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/548?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=klimm&searchid=
Other Participant(s): ECOG
Protocol(s): JHD06
SWOG
Cook JR, Goldman B, Tubbs RR, Rimsza L, LeBlanc M, Stiff P, Fisher R: MYC Protein Expression,
but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive
B-Cell Lymphomas: A SWOG S9704 Correlative Study. Blood 2012; 120(21): Abst. 622.
Protocol(s): S9704
Kelly JL, Salles G, Goldman B, Fisher RI, Casasnovas O, Press O, Maloney D, Soubeyran P, Rimsza
L, LeBlanc M, Tilly, Friedberg J: Low Serum Vitamin D Levels Are Associated with Inferior Survival
in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies. Blood 2012; 120(21):
Abst. 2712.
Protocol(s): S0016, S9800, S9911
Other Cancer
ECOG
Fisch MJ, Zhao F, Manola J, Miller A, Pirl WF, Wagner LI: Patterns of antidepressant use in patients
with cancer: An analysis from SOAPP (ECOG E2Z02: Symptom outcomes and practice patterns).
ASCO Quality Care Symposium, San Diego, CA, Nov 2012. Abst. 59.
Protocol(s): E2Z02
Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT,
Northfelt DW, Sledge GW: Does unblinding of treatment assignment impact participation perceptions
in clinical trials? Society for Medical Decision Making, Phoenix, AZ, Oct 2012. P.B. # 41.
https://smdm.confex.com/smdm/2012az/webprogram/Paper7314.html
Protocol(s): E5103
Winter 2013
19 of 20
NCI/CTEP Abstracts & Activities
Abstracts with DCTD and DCP Investigators
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni
L, Valagussa P, Zujewski JA, Justice R, Loibl S, Wickerham L, Bogaerts J, Baselga J, Perou C,
Blumenthal G, Blohmer J, Mamounas E, Bergh J, Semiglazov V, Prowell T, Eidtmann H, Paik S,
Piccart M, Sridhara R, Fasching P, Swain SM, Slaets L, Tang S, Gerber B, Geyer C, Pazdur R, Ditsch
N, Rastogi P, Eiermann W, von Mincwitz G: Meta-analysis Results from the Collaborative Trials in
Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res 2012; 72(Suppl 24): Abst. S1-11.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S1-11?sid=2bed17a3-2774-42fd-a123073f4ebde791
Romond E, Suman VJ, Jeong J-H, Sledge, Jr. GW, Geyer, Jr. CE, Martino S, Rastogi P, Gralow J,
Swain SM, Winer E, Colon-Otero G, Hudis C, Paik S, Davidson N, Mamounas EP, Zujewski JA,
Wolmark N, Perez EA: Trastuzumab Plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer:
Final Planned Joint Analysis of Overall Survival (OS) from NSABP B-31 and NCCTG N9831. San
Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2012. Abst. S5-5.
Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation
(CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the
indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided,
associated trials and information in references. References only appear under one disease heading and the Lead Cooperative
Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or
CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from
other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the
required information is available. Links to online abstracts are provided if they were available at the time of publication, but there
is no guarantee that these links will remain active.
Winter 2013
20 of 20

Winter 2013

Transcription

Similar documents

The Flipside Newsletter Spring 2014

Cognitively Guided Instruction (CGI) Grade 1 – Test 4

SELENA-SLEDAI* A TOOL TO ASSESS DISEASE ACTIVITY IN

The Breakers Palm Beach

Print Version

Unirea-Canton - Saint Michael Romanian Byzantine

CGI Corrugated

- Punto y Raya Festival